Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Promises More Deals Under Dolan: Zimmer, Clairol Bidding Continues

Executive Summary

Bristol-Myers Squibb is committed to active deal-making during the start of the Dolan period.

You may also be interested in...



Novartis Says Pharma Needs More Than Drugs; Investors May Be Persuaded

Pharmaceutical companies should diversify their business portfolios to maximize growth, Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh said Sept. 27

Novartis Says Pharma Needs More Than Drugs; Investors May Be Persuaded

Pharmaceutical companies should diversify their business portfolios to maximize growth, Novartis Head of Corporate Mergers & Acquisitions Nayan Gregory Parekh said Sept. 27

Bristol Has “Critical Mass” In R&D And Sales; Faces Tough 2004

Bristol-Myers Squibb believes it has the "critical mass" in R&D and sales to continue as a stand-alone company, CEO Peter Dolan said Jan. 29 during the company's year end earnings call

Related Content

UsernamePublicRestriction

Register

PS037321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel